Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company’s EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster...
Bonti, a privately held, clinical-stage biotechnology company, announced topline...
For a medspa or medical aesthetic practice to grow and prosper, it’s crucial to find...
When New York City-based dermatologist Eric Schweiger, MD, opened a private practice...
It is not uncommon for an employee to leave a company and join a competitor’s business...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 By Angela (Miller) Hamilton, Facebook Marketing Expert at ReachLocal
With more than 1.71 billion active users on Facebook, social media advertising is an important way for medspas and medical practices to reach local consumers online. Most facilties have a company page and perhaps purchase a few...
|
 By Paul Edwards, CEO of CEDR HR Solutions
There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away.
Despite the many...
|
Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company’s EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (two to four weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products.
For the randomized, placebo-controlled, double-blind trial, EB-001A or placebo was administered to the frontalis muscle immediately after Mohs surgery for skin lesions in the forehead in 12 subjects (eight active, four placebo). Subjects were followed up to 90 days post-treatment. Per the company’s release, EB-001A was well tolerated with no drug-related adverse events. It appeared to provide maximum benefit during the acute scar formation phase as the surgical wounds healed. Numerical improvements in clinical investigator-reported results and in key patient-reported outcomes suggest EB-001A may improve the wound healing process.
Based on Visual Analog Scale (VAS...
Bob Rhatigan, CEO of Merz North America, has been appointed to a new position in the company, president and CEO of Merz-Americas effective September 1. This expands Rhatigan’s leadership of Merz’s North American business as he assumes responsibility for Latin America and will oversee the overall commercial strategy for the company’s newly created “Americas Region.” In addition, Frank Brandt-Pollmann has been promoted to area vice president, Latin America. He will lead Merz’s business operations across Latin America and report directly to Rhatigan.
“We are confident that under the leadership of Bob Rhatigan and Frank Brandt-Pollmann, Merz in the Americas will be well-positioned to execute on our global vision to become the most admired, trusted and innovative aesthetics and neurotoxin company,” said Philip Burchard, CEO of Merz. “Moreover, I would particularly like to thank Beat Neukom, CFO of Merz Group, for his extraordinary commitment and contributions as interim region head, Latin America. For the past two years—and in addition to his CFO responsibilities—Beat has led the team in Latin America through significant changes with a focus on increasing revenue in strategic business areas and establishing a culture of...
New York-based Plastic and Reconstructive Surgeon Lara Devgan, MD, has joined RealSelf as the company’s first chief medical officer. She will act as senior medical advisor and spokesperson for the company, reporting to RealSelf CEO and Founder Tom Seery. Dr. Devgan will dedicate a portion of her time to RealSelf as a spokesperson and as counsel on services and practices to further support the company’s mission to help consumers make more confident decisions and connect them with the right medical professionals.
“Adding a chief medical officer to the RealSelf team adds important perspective and expands our commitment to transparency and empowering consumers to make smart, confident decisions about cosmetic treatments,” said Seery. “Dr. Devgan brings an incredible range of experience along with deep commitment and passion for RealSelf and for educating consumers and reducing stigmas.”
Based in New York City, Dr. Devgan received her bachelor's degree from Yale University, her medical degree and master’s of public health from Johns Hopkins Medical School and completed her residency and fellowship in plastic and reconstructive surgery at New York Presbyterian Hospital, the University Hospital of Columbia and Cornell...
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
